Henning Schmidt, Lars Brand, Caroline Stucke-Ring, Janine Schliemann, Christoph Kessler, Torsten Harrach, Saliha Mohr, Michael Görlich, Dennis Marra, Alessandro Hillejan, Ludger Müller-Tidow, Carsten Lenz, Georg Wardelmann, Eva Wiewrodt, Rainer Berdel, Wolfgang E. Schwöppe, Christian Hartmann, Wolfgang <i>In vivo</i> therapeutic activity of systemic tTF-NGR against CD13+ A549 tumor xenografts. <p>To investigate CD13 expression flow cytometry was performed with a monoclonal PE-labeled anti-CD13 antibody. CD13 expression was found in 47% of the A549 lung cancer cells (green, control; purple, CD13) (<b>Fig. 3A</b>). Following treatment with tTF-NGR (1 mg tTF-NGR/kg x4 (arrows); i.v.; n = 4 CD-1 nude mice) tumor growth of subcutaneous A549 xenotransplants was reduced as compared to the saline control group (n = 6) CD-1 nude mice (<b>Fig. 3B)</b>. The CD13 expression in subcutaneous A549 xenotransplant is demonstrated by immunofluorescence; since the antibodies used for CD13 and CD31 staining are species-specific for human CD13 and CD31, vascular and perivascular staining were not assayed in the xenografts (<b>Fig. 3C</b>).</p> Results CD 13 expression;270 NSCLC patients;lung cancer histologies;CD 13-targeted tissue factor tTF-NGR;NSCLC patients;CD 13 expression;Microarray-based mRNA analysis;CD 13 protein expression;549 lung carcinoma xenotransplants;CD 13-targeted fusion protein tTF-NGR;non-small cell lung cancer Background Aminopeptidase N;CD 13 mRNA expression;NSCLC study cohort;KM plotter database;CD 13;III;549 tumor growth 2017-06-12
    https://plos.figshare.com/articles/figure/_i_In_vivo_i_therapeutic_activity_of_systemic_tTF-NGR_against_CD13_A549_tumor_xenografts_/5101654
10.1371/journal.pone.0177146.g003